125 related articles for article (PubMed ID: 37250814)
1. XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness.
John OO; Olabode ON; Lucero-Prisno Iii DE; Adebimpe OT; Singh A
J Taibah Univ Med Sci; 2023 Dec; 18(6):1285-1287. PubMed ID: 37250814
[TBL] [Abstract][Full Text] [Related]
2. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
Parums DV
Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.
Sil D; Gautam S; Saxena S; Joshi S; Kumar D; Mehta A; Jindal P; Sharma S; Pandey P; Diksha ; Singh A
Curr Drug Targets; 2024 May; ():. PubMed ID: 38726782
[TBL] [Abstract][Full Text] [Related]
4. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
[TBL] [Abstract][Full Text] [Related]
5. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters.
Halfmann PJ; Uraki R; Kuroda M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Kawaoka Y
EBioMedicine; 2023 Jul; 93():104677. PubMed ID: 37352827
[TBL] [Abstract][Full Text] [Related]
6. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.
Faraone JN; Qu P; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep Med; 2023 May; 4(5):101049. PubMed ID: 37148877
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India - a cohort study.
Selvavinayagam ST; Karishma SJ; Hemashree K; Yong YK; Suvaithenamudhan S; Rajeshkumar M; Aswathy B; Kalaivani V; Priyanka J; Kumaresan A; Kannan M; Gopalan N; Chandramathi S; Vignesh R; Murugesan A; Anshad AR; Ganesh B; Joseph N; Babu H; Govindaraj S; Larsson M; Kandasamy SL; Palani S; Singh K; Byrareddy SN; Velu V; Shankar EM; Raju S
Lancet Reg Health Southeast Asia; 2023 Dec; 19():100272. PubMed ID: 38076717
[TBL] [Abstract][Full Text] [Related]
8. Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?
Ngiam JN; Al-Mubaarak A; Maurer-Stroh S; Tambyah PA
Singapore Med J; 2022 Dec; ():. PubMed ID: 36648003
[TBL] [Abstract][Full Text] [Related]
9. Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2.
Parums DV
Med Sci Monit; 2023 Sep; 29():e942244. PubMed ID: 37654205
[TBL] [Abstract][Full Text] [Related]
10. The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity.
DeGrasse DC; Black SD
Cureus; 2023 Jun; 15(6):e40148. PubMed ID: 37313287
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
[TBL] [Abstract][Full Text] [Related]
12. A New-fangled COVID-19 Variant, Eris, Might be the One to Lookout in 2023 or far from Over.
Ray SK; Mukherjee S
Infect Disord Drug Targets; 2024 Jan; ():. PubMed ID: 38258765
[TBL] [Abstract][Full Text] [Related]
13. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.
Nazmunnahar ; Ahmed I; Islam MR
Health Sci Rep; 2023 Mar; 6(3):e1127. PubMed ID: 36875932
[TBL] [Abstract][Full Text] [Related]
14. An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China.
Zhang M; Chen Z; Zhou J; Zhao X; Chen Y; Sun Y; Liu Z; Gu W; Luo C; Fu X; Zhao X
Biosaf Health; 2022 Dec; 4(6):406-409. PubMed ID: 36320663
[TBL] [Abstract][Full Text] [Related]
15. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
[TBL] [Abstract][Full Text] [Related]
16. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
[TBL] [Abstract][Full Text] [Related]
17. Wastewater surveillance of SARS-CoV-2 variants in October-November 2022 in Italy: detection of XBB.1, BA.2.75 and rapid spread of the BQ.1 lineage.
La Rosa G; Brandtner D; Bonanno Ferraro G; Veneri C; Mancini P; Iaconelli M; Lucentini L; Del Giudice C; Orlandi L; ; Suffredini E
Sci Total Environ; 2023 May; 873():162339. PubMed ID: 36813191
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV CH.1.1 Variant: Genomic and Structural Insight.
Bazzani L; Imperia E; Scarpa F; Sanna D; Casu M; Borsetti A; Pascarella S; Petrosillo N; Cella E; Giovanetti M; Ciccozzi M
Infect Dis Rep; 2023 May; 15(3):292-298. PubMed ID: 37367188
[TBL] [Abstract][Full Text] [Related]
19. The assessment of Twitter discourse on the new COVID-19 variant, XBB.1.5, through social network analysis.
Yuda Kusuma I; Pratiwi H; Fitri Khairunnisa S; Ayu Eka Pitaloka D; Arizandi Kurnianto A
Vaccine X; 2023 Aug; 14():100322. PubMed ID: 37317688
[TBL] [Abstract][Full Text] [Related]
20. Chasing SARS-CoV-2 XBB.1.16 Recombinant Lineage in India and the Clinical Profile of XBB.1.16 Cases in Maharashtra, India.
Karyakarte RP; Das R; Rajmane MV; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Kulkarni PP; Nizarudeen S; Joshi S; Karmodiya K; Potdar V
Cureus; 2023 Jun; 15(6):e39816. PubMed ID: 37397651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
